CAI Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
275.4M
+4.4%
263.7M
+22.0%
216.2M
-26.2%
292.9M
+35.1%
216.8M
Cost of Revenue
93.1M
+10.6%
84.1M
+12.4%
74.8M
+4.0%
72.0M
+3.8%
69.3M
Gross Profit
182.3M
+1.5%
179.6M
+27.1%
141.3M
-36.0%
220.9M
+49.8%
147.5M
Operating Expenses
163.0M
+6.7%
152.7M
+12.2%
136.1M
+2.7%
132.5M
+15.4%
114.9M
R&D
33.8M
+4.6%
32.4M
+3.3%
31.3M
-1.7%
31.8M
+47.3%
21.6M
SG&A
129.1M
+7.3%
120.3M
+14.9%
104.8M
+4.1%
100.7M
+8.0%
93.2M
Operating Income
19.3M
-28.3%
26.9M
+409.8%
5.3M
-94.0%
88.4M
+170.9%
32.6M
EBITDA
25.9M
-22.5%
33.5M
+223.4%
10.3M
-88.8%
92.7M
+147.1%
37.5M
Net Income
15.3M
+2494.0%
-637000
-24.9%
-510000
-100.6%
82.0M
+236.9%
24.3M
EPS (Basic)
$0.05
$0.00
$0.00
-100.0%
$0.29
+222.2%
$0.09
EPS (Diluted)
$0.05
$0.00
$0.00
-100.0%
$0.30
+275.0%
$0.08
Shares (Diluted)
295.1M
+4.3%
282.9M
+0.1%
282.6M
+4.2%
271.1M
-8.8%
297.2M
Caris Life Sciences (CAI) — Financials